Cargando…

Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome

BACKGROUND: Antiphospholipid syndrome (APS) is a disorder associated with thromboembolic diseases, including acute myocardial infarction (AMI). Given that AMI is a relatively common condition with poor prognostic features, identification of risk factors for AMI in APS is important. METHODS: A retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Yuzhou, Zhao, Yawei, Li, Gongming, Ye, Hua, Zhou, Yunshan, Hou, Chang, Wang, Lan, Guo, Jianping, Li, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294316/
https://www.ncbi.nlm.nih.gov/pubmed/35865377
http://dx.doi.org/10.3389/fcvm.2022.871011
_version_ 1784749825041891328
author Gan, Yuzhou
Zhao, Yawei
Li, Gongming
Ye, Hua
Zhou, Yunshan
Hou, Chang
Wang, Lan
Guo, Jianping
Li, Chun
author_facet Gan, Yuzhou
Zhao, Yawei
Li, Gongming
Ye, Hua
Zhou, Yunshan
Hou, Chang
Wang, Lan
Guo, Jianping
Li, Chun
author_sort Gan, Yuzhou
collection PubMed
description BACKGROUND: Antiphospholipid syndrome (APS) is a disorder associated with thromboembolic diseases, including acute myocardial infarction (AMI). Given that AMI is a relatively common condition with poor prognostic features, identification of risk factors for AMI in APS is important. METHODS: A retrospective cohort study was performed consisting of 332 patients with APS, and 239 patients with thrombotic APS were finally included. Patients were followed up in the outpatient department for 5 years. Clinical data and laboratory parameters were analyzed to identify the risk factors for AMI in APS. The primary and secondary clinical outcomes were all-cause mortality and recurrence of thrombosis, respectively. RESULTS: AMI was observed in 12.1% (29/239) of patients with APS. Compared to patients without AMI, patients with AMI had multiple organ thrombosis (55.1 vs. 34.3%, p = 0.029), recurrent thrombosis (58.6 vs. 34.3%, p = 0.011), a higher incidence of atherosclerosis (62.1 vs. 23.8%, p < 0.001), higher neutrophil count (×10(9)/L) [4.68 (3.25, 8.17) vs. 3.71 (2.64, 5.80), p = 0.036], longer QT interval (ms) [438 ms (423, 454) vs. 425 ms (410, 446), p = 0.016], and fewer venous thrombosis events (27.6 vs. 63.3%, p < 0.001). Multivariate logistic regression analysis (adjusted for age and gender) identified several factors that were positively associated with AMI, including multiple organ thrombosis [odds ratio (OR) 8.862, 95% confidence interval (CI): 1.817–43.212, p = 0.007), atherosclerosis (OR 5.397, 95%CI: 1.943–14.994, p = 0.001), and elevated neutrophil count (>6.3 ×10(9)/L) (OR 3.271, 95%CI: 1.268–8.440, p = 0.014). The venous thrombosis was negatively associated with AMI (OR 0.106, 95%CI: 0.036–0.314, p < 0.001). Kaplan–Meier analysis revealed that the recurrence rates of arterial thrombosis differed significantly between patients with AMI and those without AMI [hazard ratio (HR) = 3.307, p = 0.038]. CONCLUSION: Atherosclerosis, multiple organ thrombosis, an increased number of neutrophils are variables positively associated with AMI in APS, and venous thrombosis had a negative association with AMI. AMI only predicts the subsequent recurrence of arterial thrombosis. These findings suggest that distinct pathophysiological mechanisms may exist and contribute to the development of venous or arterial thrombotic APS.
format Online
Article
Text
id pubmed-9294316
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92943162022-07-20 Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome Gan, Yuzhou Zhao, Yawei Li, Gongming Ye, Hua Zhou, Yunshan Hou, Chang Wang, Lan Guo, Jianping Li, Chun Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Antiphospholipid syndrome (APS) is a disorder associated with thromboembolic diseases, including acute myocardial infarction (AMI). Given that AMI is a relatively common condition with poor prognostic features, identification of risk factors for AMI in APS is important. METHODS: A retrospective cohort study was performed consisting of 332 patients with APS, and 239 patients with thrombotic APS were finally included. Patients were followed up in the outpatient department for 5 years. Clinical data and laboratory parameters were analyzed to identify the risk factors for AMI in APS. The primary and secondary clinical outcomes were all-cause mortality and recurrence of thrombosis, respectively. RESULTS: AMI was observed in 12.1% (29/239) of patients with APS. Compared to patients without AMI, patients with AMI had multiple organ thrombosis (55.1 vs. 34.3%, p = 0.029), recurrent thrombosis (58.6 vs. 34.3%, p = 0.011), a higher incidence of atherosclerosis (62.1 vs. 23.8%, p < 0.001), higher neutrophil count (×10(9)/L) [4.68 (3.25, 8.17) vs. 3.71 (2.64, 5.80), p = 0.036], longer QT interval (ms) [438 ms (423, 454) vs. 425 ms (410, 446), p = 0.016], and fewer venous thrombosis events (27.6 vs. 63.3%, p < 0.001). Multivariate logistic regression analysis (adjusted for age and gender) identified several factors that were positively associated with AMI, including multiple organ thrombosis [odds ratio (OR) 8.862, 95% confidence interval (CI): 1.817–43.212, p = 0.007), atherosclerosis (OR 5.397, 95%CI: 1.943–14.994, p = 0.001), and elevated neutrophil count (>6.3 ×10(9)/L) (OR 3.271, 95%CI: 1.268–8.440, p = 0.014). The venous thrombosis was negatively associated with AMI (OR 0.106, 95%CI: 0.036–0.314, p < 0.001). Kaplan–Meier analysis revealed that the recurrence rates of arterial thrombosis differed significantly between patients with AMI and those without AMI [hazard ratio (HR) = 3.307, p = 0.038]. CONCLUSION: Atherosclerosis, multiple organ thrombosis, an increased number of neutrophils are variables positively associated with AMI in APS, and venous thrombosis had a negative association with AMI. AMI only predicts the subsequent recurrence of arterial thrombosis. These findings suggest that distinct pathophysiological mechanisms may exist and contribute to the development of venous or arterial thrombotic APS. Frontiers Media S.A. 2022-07-05 /pmc/articles/PMC9294316/ /pubmed/35865377 http://dx.doi.org/10.3389/fcvm.2022.871011 Text en Copyright © 2022 Gan, Zhao, Li, Ye, Zhou, Hou, Wang, Guo and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Gan, Yuzhou
Zhao, Yawei
Li, Gongming
Ye, Hua
Zhou, Yunshan
Hou, Chang
Wang, Lan
Guo, Jianping
Li, Chun
Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome
title Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome
title_full Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome
title_fullStr Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome
title_full_unstemmed Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome
title_short Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome
title_sort risk factors and outcomes of acute myocardial infarction in a cohort of antiphospholipid syndrome
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294316/
https://www.ncbi.nlm.nih.gov/pubmed/35865377
http://dx.doi.org/10.3389/fcvm.2022.871011
work_keys_str_mv AT ganyuzhou riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome
AT zhaoyawei riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome
AT ligongming riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome
AT yehua riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome
AT zhouyunshan riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome
AT houchang riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome
AT wanglan riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome
AT guojianping riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome
AT lichun riskfactorsandoutcomesofacutemyocardialinfarctioninacohortofantiphospholipidsyndrome